NTLA · NASDAQ · In Vitro & In Vivo Diagnostic Substances
No fund moves found
Nothing has been reported for this company in this source yet.
Institutions reporting a stake, Q2 2026
327
+23 vs Q1 2026
Share of stock reported
144M
shares, no single share count to compare with
Change vs Q1 2026
+33.5M shares
50 new positions, 28 positions closed
Reported in 13F filings, which cover managers over $100M and include double counting. A 13F shows holdings on the last day of the quarter, not when shares were bought or sold. Change counts the 323 managers that reported both quarters.
Source: SEC Form 13F data sets, every filer, common stock only (options and bonds left out); 9 managers also reported puts and 14 managers calls. Amendments are applied; lines whose value was filed in thousands are scaled, and lines whose shares and value disagree are left out.